Leukemia research最新文献

英文中文

Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan Ruxolitinib在现实世界骨髓纤维化患者中的安全性和有效性：台湾一项为期两年的观察性研究。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-23 DOI: 10.1016/j.leukres.2024.107601

Ming-Chung Kuo , Chien-Chin Lin , Hsuan-Yu Lin, Jyh-Pyng Gau, Ming-Chung Wang, Ming-Chih Chang, Tsung-Chih Chen, Shih-Peng Yeh, Yeu-Chin Chen, Cih-En Huang, I-Ju Chiang, Hao-Wei Cheng, Yee-Ming Lee, Fan-Chen Ku, Cheng-Shyong Chang

引用次数: 0

The phylogenetic age paradox of non-coding RNAs 非编码 RNA 的系统发育年龄悖论。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-22 DOI: 10.1016/j.leukres.2024.107600

Martin S. Staege

引用次数: 0

A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure 骨髓细胞白血病 1 (MCL1) 抑制剂 tapotoclax (AMG 176) 对低甲基化药物治疗失败后骨髓增生异常综合征患者的 I 期研究。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-22 DOI: 10.1016/j.leukres.2024.107602

Kelly S. Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, Guillermo Montalban-Bravo, Danielle E. Hammond, Mahesh Swaminathan, Alexandre Bazinet, Jacqueline Kimberley, Kristy Bodden, Heather Schneider, Xiao Qin Dong, Sherry A. Pierce, Xuelin Huang, Elias J. Jabbour, Hagop M. Kantarjian, Guillermo Garcia-Manero

引用次数: 0

Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study BCR::ABL1酪氨酸激酶抑制剂对慢性丙型肝炎病毒感染的癌症患者的病毒学效应和肝毒性：前瞻性研究。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-03 DOI: 10.1016/j.leukres.2024.107597

Khalis Mustafayev, Eduardo Yepez Guevara, Courtney D. DiNardo, Elias Jabbour, Issa C. Ghayas, Ravin Ratan, Naveen Pemmaraju, Harrys A. Torres

引用次数: 0

Therapeutic advances for the management of adult T cell leukemia: Where do we stand? 成人 T 细胞白血病的治疗进展：现状如何？

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-02 DOI: 10.1016/j.leukres.2024.107598

Hiba El Hajj , Olivier Hermine , Ali Bazarbachi

Adult T cell leukemia (ATL) is an aggressive blood malignancy secondary to chronic infection with the human T cell leukemia virus type I (HTLV-1) retrovirus. ATL encompasses four subtypes (acute, lymphoma, chronic, and smoldering), which exhibit different clinical characteristics and respond differently to various treatment strategies. Yet, all four subtypes are characterized by a dismal long-term prognosis and a low survival rate. While antiretroviral therapy improves overall survival outcomes in smoldering and chronic subtypes, survival remains poor in lymphoma subtypes despite their good response to intensive chemotherapy. Nonetheless, acute ATL remains the most aggressive form associated with profound immunosuppression, chemo-resistance and dismal prognosis. Targeted therapies such as monoclonal antibodies, epigenetic therapies, and arsenic/IFN, emerged as promising therapeutic approaches in ATL. Allogeneic hematopoietic cell transplantation is the only potentially curative modality, alas applicable to only a small percentage of patients. The recent findings demonstrating the expression of the viral oncoprotein Tax in primary ATL cells from patients with acute or chronic ATL, albeit at low levels, and their dependence on continuous Tax expression for their survival, position ATL as a virus-addicted leukemia and validates the rationale of anti-viral treatment strategies. This review provides a comprehensive overview on conventional, anti-viral and targeted therapies of ATL, with emphasis on Tax-targeted therapied in the pre-clinical and clinical settings.

成人 T 细胞白血病（ATL）是一种继发于人类 T 细胞白血病病毒 I 型（HTLV-1）逆转录病毒慢性感染的侵袭性血液恶性肿瘤。ATL 包括四种亚型（急性、淋巴瘤、慢性和烟雾型），它们表现出不同的临床特征，对各种治疗策略的反应也不尽相同。然而，这四种亚型的长期预后都很糟糕，存活率很低。抗逆转录病毒疗法可改善烟熏型和慢性亚型患者的总体存活率，而淋巴瘤亚型患者尽管对强化化疗反应良好，但存活率仍然很低。尽管如此，急性ATL仍然是最具侵袭性的淋巴瘤，具有严重的免疫抑制、化疗耐药和预后不良等特点。单克隆抗体、表观遗传疗法和砷/IFN等靶向疗法成为治疗ATL的有前途的方法。异基因造血细胞移植是唯一可能治愈的方法，但只适用于一小部分患者。最近的研究结果表明，急性或慢性 ATL 患者的原发性 ATL 细胞中存在病毒肿瘤蛋白 Tax 的表达（尽管水平较低），而且这些细胞的存活依赖于 Tax 的持续表达，这将 ATL 定义为一种病毒上瘾的白血病，并验证了抗病毒治疗策略的合理性。本综述全面概述了 ATL 的常规、抗病毒和靶向疗法，重点是临床前和临床环境中的 Tax 靶向疗法。

{"title":"Therapeutic advances for the management of adult T cell leukemia: Where do we stand?","authors":"Hiba El Hajj , Olivier Hermine , Ali Bazarbachi","doi":"10.1016/j.leukres.2024.107598","DOIUrl":"10.1016/j.leukres.2024.107598","url":null,"abstract":"<div><div>Adult T cell leukemia (ATL) is an aggressive blood malignancy secondary to chronic infection with the human T cell leukemia virus type I (HTLV-1) retrovirus. ATL encompasses four subtypes (acute, lymphoma, chronic, and smoldering), which exhibit different clinical characteristics and respond differently to various treatment strategies. Yet, all four subtypes are characterized by a dismal long-term prognosis and a low survival rate. While antiretroviral therapy improves overall survival outcomes in smoldering and chronic subtypes, survival remains poor in lymphoma subtypes despite their good response to intensive chemotherapy. Nonetheless, acute ATL remains the most aggressive form associated with profound immunosuppression, chemo-resistance and dismal prognosis. Targeted therapies such as monoclonal antibodies, epigenetic therapies, and arsenic/IFN, emerged as promising therapeutic approaches in ATL. Allogeneic hematopoietic cell transplantation is the only potentially curative modality, alas applicable to only a small percentage of patients. The recent findings demonstrating the expression of the viral oncoprotein Tax in primary ATL cells from patients with acute or chronic ATL, albeit at low levels, and their dependence on continuous Tax expression for their survival, position ATL as a virus-addicted leukemia and validates the rationale of anti-viral treatment strategies. This review provides a comprehensive overview on conventional, anti-viral and targeted therapies of ATL, with emphasis on Tax-targeted therapied in the pre-clinical and clinical settings.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107598"},"PeriodicalIF":2.1,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemotherapy and allo-HSCT for young patients with aggressive ATL 对侵袭性ATL年轻患者进行化疗和异基因造血干细胞移植。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-09-27 DOI: 10.1016/j.leukres.2024.107596

Shigeo Fuji

Adult T-cell leukemia-lymphoma (ATL) is an aggressive malignancy with a poor prognosis, especially for patients with the aggressive subtype. While conventional chemotherapy offers short-term disease control, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most promising curative approach for young, transplant-eligible patients. This review focuses on current treatment strategies for aggressive ATL in this specific population. We discuss the rationale for early upfront allo-HSCT following induction chemotherapy. The advent of allo-HSCT using alternative donors, particularly haploidentical HCT, has broadened the applicability of early upfront allo-HSCT in patients with aggressive ATL worldwide. Finally, we address emerging therapies that may improve outcomes in the context of allo-HSCT, paving the way for further advancements in the treatment of aggressive ATL.

成人T细胞白血病淋巴瘤（ATL）是一种侵袭性恶性肿瘤，预后较差，尤其是侵袭性亚型患者。虽然传统化疗能在短期内控制病情，但对于符合移植条件的年轻患者来说，异基因造血干细胞移植（allo-HSCT）仍是最有希望治愈的方法。本综述将重点讨论目前针对这一特殊人群的侵袭性ATL的治疗策略。我们讨论了在诱导化疗后尽早进行前期allo-HSCT的理由。使用替代供者，尤其是单倍体同种异基因造血干细胞移植（HCT）的出现扩大了早期先期同种异基因造血干细胞移植在全球侵袭性 ATL 患者中的适用性。最后，我们探讨了可改善allo-HSCT治疗效果的新兴疗法，为进一步推动侵袭性ATL的治疗铺平了道路。

引用次数: 0

Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis 长非编码 RNA 在急性髓性白血病中的临床意义：系统回顾与荟萃分析

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-09-23 DOI: 10.1016/j.leukres.2024.107595

Priya , Manoj Garg , Rashmi Talwar , Mohit Bharadwaj , Munindra Ruwali , Amit Kumar Pandey

Background

Long noncoding RNAs (lncRNAs) may function as prognostic biomarkers in acute myeloid leukaemia (AML). However, it is still unknown exactly how significant lncRNAs are for the prognosis of AML. With a focus on their prognostic and therapeutic potential, the study aimed to provide a comprehensive review of the literature regarding the role of lncRNAs in AML.

Method

Pub Med, The Cochrane Library, Embase, Science Direct, Web of science, Scopus, and Google scholar were searched until November, 2023. Original publications of any type exploring the prognostic and therapeutic potential of lncRNAs in AML patients were included. Heterogeneity and publication bias were examined using the I² test and a funnel plot, respectively. To quantify the relationship between various lncRNA expression in AML patient survival, odds ratios (ORs) or hazards ratios (HRs) with 95 % confidence intervals (CIs) were pooled. Quality of studies was assessed using the Critical Appraisal Checklists for Studies created by the Joanna Briggs Institute (JBI).

Results

Twenty-seven studies including 5665 subjects were selected for the final analysis. In patients with AML, abnormal lncRNA expression has been associated with significant worse overall survival (pooled HR = 2.05, 95 % CI = 1.79–2.30, P <0.001), shorter disease-free survival (pooled HR = 2.17, 95 % CI = 1.13–3.22, P< 0.001), and lower complete remission rate (pooled HR = 0.27, 95 % CI = 0.11–0.43, P< 0.001). Poor prognoses have been attributed to increased expression of HOX transcript antisense intergenic RNA (HOTAIR), Promoter Of CDKN1A Antisense DNA Damage Activated RNA (PANDAR), Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), RP11–222K16.2, Taurine Upregulated Gene 1 (TUG1), Small Nucleolar RNA Host Gene 5 (SNHG5), Growth Arrest Specific 5 (GAS5), and H19 and decreased expression of IGF1R Antisense Imprinted Non-Protein Coding RNA (IRAIN).

Conclusion

The prognoses of AML patients are significantly associated with abnormally expressed lncRNAs, which may be used as prognostic indicators for predicting the patient outcomes.

背景长非编码RNA（lncRNA）可作为急性髓性白血病（AML）的预后生物标志物。然而，目前尚不清楚lncRNA对急性髓性白血病预后的确切意义。本研究以其预后和治疗潜力为重点，旨在对有关lncRNAs在AML中作用的文献进行全面综述。研究方法检索了Pub Med、The Cochrane Library、Embase、Science Direct、Web of science、Scopus和Google scholar，直至2023年11月。纳入了探讨 lncRNAs 在急性髓细胞性白血病患者中的预后和治疗潜力的任何类型的原始出版物。分别使用 I2 检验和漏斗图检验异质性和发表偏倚。为了量化各种lncRNA表达与AML患者生存之间的关系，对带有95%置信区间（CI）的几率比（OR）或危险比（HR）进行了汇总。研究质量采用乔安娜-布里格斯研究所（JBI）制定的 "研究关键评估清单"（Critical Appraisal Checklists for Studies）进行评估。在急性髓细胞性白血病患者中，lncRNA表达异常与较差的总生存期（汇总HR = 2.05，95 % CI = 1.79-2.30，P<0.001）、较短的无病生存期（汇总HR = 2.17，95 % CI = 1.13-3.22，P<0.001）和较低的完全缓解率（汇总HR = 0.27，95 % CI = 0.11-0.43，P<0.001）明显相关。预后不良的原因是 HOX 转录本反义基因间 RNA（HOTAIR）、Promoter Of CDKN1A Antisense DNA Damage Activated RNA（PANDAR）、Metastasis Associated Lung Adenocarcinoma Transcript 1（MALAT1）、RP11-222K16.2、牛磺酸上调基因1（TUG1）、小核极RNA宿主基因5（SNHG5）、生长停滞特异性5（GAS5）和H19的表达以及IGF1R反义印迹非蛋白编码RNA（IRAIN）的表达减少。

{"title":"Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis","authors":"Priya , Manoj Garg , Rashmi Talwar , Mohit Bharadwaj , Munindra Ruwali , Amit Kumar Pandey","doi":"10.1016/j.leukres.2024.107595","DOIUrl":"10.1016/j.leukres.2024.107595","url":null,"abstract":"<div><h3>Background</h3><div>Long noncoding RNAs (lncRNAs) may function as prognostic biomarkers in acute myeloid leukaemia (AML). However, it is still unknown exactly how significant lncRNAs are for the prognosis of AML. With a focus on their prognostic and therapeutic potential, the study aimed to provide a comprehensive review of the literature regarding the role of lncRNAs in AML.</div></div><div><h3>Method</h3><div>Pub Med, The Cochrane Library, Embase, Science Direct, Web of science, Scopus, and Google scholar were searched until November, 2023. Original publications of any type exploring the prognostic and therapeutic potential of lncRNAs in AML patients were included. Heterogeneity and publication bias were examined using the I<sup>2</sup> test and a funnel plot, respectively. To quantify the relationship between various lncRNA expression in AML patient survival, odds ratios (ORs) or hazards ratios (HRs) with 95 % confidence intervals (CIs) were pooled. Quality of studies was assessed using the Critical Appraisal Checklists for Studies created by the Joanna Briggs Institute (JBI).</div></div><div><h3>Results</h3><div>Twenty-seven studies including 5665 subjects were selected for the final analysis. In patients with AML, abnormal lncRNA expression has been associated with significant worse overall survival (pooled HR = 2.05, 95 % CI = 1.79–2.30, P <0.001), shorter disease-free survival (pooled HR = 2.17, 95 % CI = 1.13–3.22, P< 0.001), and lower complete remission rate (pooled HR = 0.27, 95 % CI = 0.11–0.43, P< 0.001). Poor prognoses have been attributed to increased expression of HOX transcript antisense intergenic RNA (HOTAIR), Promoter Of CDKN1A Antisense DNA Damage Activated RNA (PANDAR), Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), RP11–222K16.2, Taurine Upregulated Gene 1 (TUG1), Small Nucleolar RNA Host Gene 5 (SNHG5), Growth Arrest Specific 5 (GAS5), and H19 and decreased expression of IGF1R Antisense Imprinted Non-Protein Coding RNA (IRAIN).</div></div><div><h3>Conclusion</h3><div>The prognoses of AML patients are significantly associated with abnormally expressed lncRNAs, which may be used as prognostic indicators for predicting the patient outcomes.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107595"},"PeriodicalIF":2.1,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience 青少年和年轻成人急性髓性白血病患者与中年患者的预后比较：单一中心的回顾性经验。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-09-21 DOI: 10.1016/j.leukres.2024.107586

RuiQi Chen, Mohaned AlHumaid, Georgina Daher-Reyes, Eshetu G. Atenafu, Steven Chan, Vikas Gupta, Dawn Maze, Andre C. Schuh, Mark D. Minden, Karen Yee, Aaron D. Schimmer, Hassan Sibai

Adult acute myeloid leukemia (AML) patients under the age of 60 often receive similar intensive treatments, while outcomes between the adolescent and young adult (AYA) age group (18−39) and middle-aged adults (40–60 years) were seldom reported. We aim to study the characteristics and outcomes of AYA patients in comparison to middle-aged adults. A retrospective analysis was performed on AYA patients treated at Princess Margaret Cancer Center between 2008 and 2018. The primary outcomes include overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM).

A total of 174 AYA patients and 176 middle-aged patients were included, with propensity score matching adjusting for potential major confounders. Comparing AYA and middle-aged patients, 5-year OS rates were similar at 54.6 % vs. 56.5 % (p=0.91), CIR rates at 29.5 % vs. 23.1 % (p=0.31), and similar NRM rates. Notably, non-transplanted AYA patients had a significantly higher CIR (39.8 %) compared to middle-aged patients (19.6 %) (p=0.0324), with more primary refractory/early relapsing disease. An observed trend toward improved OS in AYA patients post-2015 coincided with FLAG-IDA and haploidentical transplant implementations.

In conclusion, the study suggests that AYA patients, particularly those not undergoing transplantation, may benefit from more intensive treatment strategies, emphasizing the need for tailored approaches in this age group.

60 岁以下的成人急性髓性白血病（AML）患者通常会接受类似的强化治疗，而青少年和年轻成人（AYA）年龄组（18-39 岁）与中年成人（40-60 岁）之间的治疗效果却鲜有报道。我们旨在研究青少年和青年患者与中年人相比的特征和疗效。我们对 2008 年至 2018 年期间在玛格丽特公主癌症中心接受治疗的青壮年患者进行了回顾性分析。主要结果包括总生存期（OS）、累积复发率（CIR）和非复发死亡率（NRM）。共纳入174名青壮年患者和176名中年患者，并对潜在的主要混杂因素进行倾向评分匹配调整。对比青壮年患者和中年患者，5年OS率相似，分别为54.6%和56.5%（P=0.91），CIR率分别为29.5%和23.1%（P=0.31），NRM率相似。值得注意的是，与中年患者（19.6%）相比，未接受移植的青壮年患者的CIR（39.8%）明显更高（p=0.0324），原发性难治/早期复发的疾病也更多。2015年后，随着FLAG-IDA和单倍体移植的实施，观察到AYA患者的OS呈改善趋势。总之，该研究表明，AYA 患者，尤其是未接受移植的患者，可能会从更密集的治疗策略中获益，这也强调了在这一年龄组中采取针对性治疗方法的必要性。

{"title":"Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience","authors":"RuiQi Chen, Mohaned AlHumaid, Georgina Daher-Reyes, Eshetu G. Atenafu, Steven Chan, Vikas Gupta, Dawn Maze, Andre C. Schuh, Mark D. Minden, Karen Yee, Aaron D. Schimmer, Hassan Sibai","doi":"10.1016/j.leukres.2024.107586","DOIUrl":"10.1016/j.leukres.2024.107586","url":null,"abstract":"<div><div>Adult acute myeloid leukemia (AML) patients under the age of 60 often receive similar intensive treatments, while outcomes between the adolescent and young adult (AYA) age group (18−39) and middle-aged adults (40–60 years) were seldom reported. We aim to study the characteristics and outcomes of AYA patients in comparison to middle-aged adults. A retrospective analysis was performed on AYA patients treated at Princess Margaret Cancer Center between 2008 and 2018. The primary outcomes include overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM).</div><div>A total of 174 AYA patients and 176 middle-aged patients were included, with propensity score matching adjusting for potential major confounders. Comparing AYA and middle-aged patients, 5-year OS rates were similar at 54.6 % vs. 56.5 % (p=0.91), CIR rates at 29.5 % vs. 23.1 % (p=0.31), and similar NRM rates. Notably, non-transplanted AYA patients had a significantly higher CIR (39.8 %) compared to middle-aged patients (19.6 %) (p=0.0324), with more primary refractory/early relapsing disease. An observed trend toward improved OS in AYA patients post-2015 coincided with FLAG-IDA and haploidentical transplant implementations.</div><div>In conclusion, the study suggests that AYA patients, particularly those not undergoing transplantation, may benefit from more intensive treatment strategies, emphasizing the need for tailored approaches in this age group.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107586"},"PeriodicalIF":2.1,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing the risk of venous thromboembolism and bleeding among patients with myeloproliferative neoplasms undergoing total knee and hip arthroplasty 评估接受全膝关节和髋关节置换术的骨髓增生性肿瘤患者发生静脉血栓栓塞和出血的风险

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-09-21 DOI: 10.1016/j.leukres.2024.107591

Josue Marquez , Samantha Simon , Jeffrey I. Zwicker, Robert Flaumenhaft, Brian Hollenbeck, Rushad Patell

引用次数: 0

Patient-centric care in myelodysplastic syndromes: A global systematic literature review and gap analysis 骨髓增生异常综合征中以患者为中心的护理：全球系统性文献回顾与差距分析

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-09-21 DOI: 10.1016/j.leukres.2024.107592

Edward P. Armstrong , Duska M. Franic , Daniel C. Malone , Patrick Mellors , Sissi V. Pham , Cristina Masseria , Lorie Mody , Cosmina Hogea

Background

Disease progression and poor prognosis in higher-risk (HR) myelodysplastic syndrome (MDS) create an urgent need for interventions to improve the patient care experience in this vulnerable population. Patient-centric physician-supported strategies in conjunction with emerging therapies can help advance overall care and improve outcomes. The objective of this study was to evaluate patient-centric care (PCC) in the treatment of HR-MDS and identify opportunities to develop strategies to address care gaps for an optimal patient care experience.

Methods

A global systematic literature review (SLR) was conducted by cross-referencing MDS/HR-MDS with PCC terms, using PubMed, Embase, and Cochrane Collaboration databases (2017–2022) in accordance with Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.

Results

In all, 59 MDS articles (45 empirical, 14 reviews) met the study inclusion criteria. Of these, 6 empirical articles focused on the HR-MDS population while none of the reviews did. Identified themes fell into 2 categories: health-related quality of life (HRQoL) and disparities. HRQoL was further categorized based on findings in the literature to include groupings of patient-reported outcomes (PROs), fatigue/frailty, and patient/preferences/treatment decisions/shared decision making (SDM).

Conclusions

With new treatments potentially on the horizon for HR-MDS, a call to action is timely to address the overall lack of empirical PCC data. The patient-centric approach presents critical opportunities for integration of physician-supported strategies with more effective first-line therapies to help optimize the journey of patients with HR-MDS and ensure meaningful outcomes by reducing patient/caregiver burden, aligning with and respecting patient preferences, and including patients as active participants in their treatment.

背景高危（HR）骨髓增生异常综合征（MDS）的疾病进展和不良预后导致迫切需要采取干预措施来改善这一脆弱人群的患者护理体验。以患者为中心的医生支持策略与新兴疗法相结合，有助于推进整体护理并改善预后。本研究的目的是评估在治疗 HR-MDS 过程中以患者为中心的护理（PCC），并确定制定策略的机会，以弥补护理差距，实现最佳的患者护理体验。方法根据系统性综述和荟萃分析首选报告项目（PRISMA）指南，使用 PubMed、Embase 和 Cochrane Collaboration 数据库（2017-2022 年），将 MDS/HR-MDS 与 PCC 术语交叉引用，进行了全球系统性文献综述（SLR）。其中，6 篇经验性文章侧重于 HR-MDS 群体，而没有一篇综述文章侧重于 HR-MDS 群体。确定的主题分为两类：与健康相关的生活质量（HRQoL）和差异。根据文献中的发现，对 HRQoL 进行了进一步分类，包括患者报告结果 (PRO)、疲劳/虚弱以及患者/偏好/治疗决定/共同决策 (SDM) 等分组。以患者为中心的方法提供了将医生支持的策略与更有效的一线疗法相结合的重要机会，有助于优化 HR-MDS 患者的治疗过程，并通过减轻患者/护理人员的负担、符合并尊重患者的偏好以及让患者积极参与治疗，确保获得有意义的治疗结果。

{"title":"Patient-centric care in myelodysplastic syndromes: A global systematic literature review and gap analysis","authors":"Edward P. Armstrong , Duska M. Franic , Daniel C. Malone , Patrick Mellors , Sissi V. Pham , Cristina Masseria , Lorie Mody , Cosmina Hogea","doi":"10.1016/j.leukres.2024.107592","DOIUrl":"10.1016/j.leukres.2024.107592","url":null,"abstract":"<div><h3>Background</h3><div>Disease progression and poor prognosis in higher-risk (HR) myelodysplastic syndrome (MDS) create an urgent need for interventions to improve the patient care experience in this vulnerable population. Patient-centric physician-supported strategies in conjunction with emerging therapies can help advance overall care and improve outcomes. The objective of this study was to evaluate patient-centric care (PCC) in the treatment of HR-MDS and identify opportunities to develop strategies to address care gaps for an optimal patient care experience.</div></div><div><h3>Methods</h3><div>A global systematic literature review (SLR) was conducted by cross-referencing MDS/HR-MDS with PCC terms, using PubMed, Embase, and Cochrane Collaboration databases (2017–2022) in accordance with Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.</div></div><div><h3>Results</h3><div>In all, 59 MDS articles (45 empirical, 14 reviews) met the study inclusion criteria. Of these, 6 empirical articles focused on the HR-MDS population while none of the reviews did. Identified themes fell into 2 categories: health-related quality of life (HRQoL) and disparities. HRQoL was further categorized based on findings in the literature to include groupings of patient-reported outcomes (PROs), fatigue/frailty, and patient/preferences/treatment decisions/shared decision making (SDM).</div></div><div><h3>Conclusions</h3><div>With new treatments potentially on the horizon for HR-MDS, a call to action is timely to address the overall lack of empirical PCC data. The patient-centric approach presents critical opportunities for integration of physician-supported strategies with more effective first-line therapies to help optimize the journey of patients with HR-MDS and ensure meaningful outcomes by reducing patient/caregiver burden, aligning with and respecting patient preferences, and including patients as active participants in their treatment.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107592"},"PeriodicalIF":2.1,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Leukemia research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀